insights_auto
Why is 524494 down 3.51%?
Dive Deeperchevron_right
524494:BOM
IPCA Laboratories Ltd
₹1,845.00
arrow_downward
-3.51%(-67.20) 1D
Oct 16, 3:30:00 PM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 524494...
Open
₹1,913.95
High
₹1,913.95
Low
₹1,812.60
Mkt. cap
468.21B
Avg. vol.
27.90K
Volume
12.00K
Dividend
0.33%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
35.74
52-wk high
₹2,039.30
52-wk low
₹1,252.95
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
Open
₹1,913.95
High
₹1,913.95
Low
₹1,812.60
Mkt. cap
468.21B
Avg. vol.
27.90K
Volume
12.00K
Dividend
0.33%
Quarterly dividend
₹1.50
Ex-dividend date
Aug 7, 2026
P/E ratio
35.74
52-wk high
₹2,039.30
52-wk low
₹1,252.95
EPS
₹51.63
Shares outstanding
126.35M
No. of employees
17K
News stories
From web sources and news partners
Trefis
·
1 hour ago
1 S&P 500 Stock Hit A 52-Week Low On Friday
StoneX
·
14 hours ago
S&P 500 Forecast: SPX set for a weekly decline led lower by tech as AI worries linger
TradingView
·
12 hours ago
$SPX: Trade Against the Crowd, Not the Economy (+92 Pts) for FX:SPX500 by AndyMorgan
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd